Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We've got lots ...
AZoLifeSciences on MSN7d
Integrating CRISPR and biomaterials engineering: Paving the way for safer gene therapiesLehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...
The global gene therapy market size was valued at USD 6.30 billion in 2024 and is projected to reach from USD 7.47 billion in ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...
The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...
Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.
BizTimes Media’s 24th annual Economic Trends event on Thursday featured insights and predictions from an economist, local business leaders and an academic ...
The company expects to submit a biologics license application for NTLA-2002 in 2026 and potentially launch it in the US in 2027.
Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...
The CONNECT2-EDO51 phase 2 trial looks at PGN-EDO51, an investigational therapy for Duchenne muscular dystrophy (DMD), and is still ongoing in the United Kingdom. The most-read gene therapy ...
Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback